Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insights to 2025 – ResearchAndMarkets.com

DUBLIN–()–The “Global Human Microbiome Immunology Therapeutics Market & Clinical Trial Insight 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome’s role in immunology practices is to transform world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

The essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then the unsuccessful implication of immunology therapies driven treatments led to an exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

Companies Mentioned

  • 4D Pharma
  • AbbVie
  • AstraZeneca plc
  • Biocodex
  • Bristol Mayer Squibb
  • Corebiome/Diversigen
  • Elogi Bioscience
  • Enterome
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • Maat Pharma
  • Merck
  • Microbiome Therapeutics
  • Novartis
  • OpenBiome
  • Pfizer
  • Rebiotix
  • Second Genome
  • Seres Therapeutics
  • Symberix
  • Takeda Pharmaceuticals
  • Vedanta Bioscience

Report Highlights:

  • Global & Regional Market Insight
  • Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025
  • US Dominates Global Market Landscape: >60% Market Share
  • Comprehensive Information on Ongoing Clinical Trials & Potential Drug Candidates
  • Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials
  • Therapeutic Applications of Microbiome Immunology by Indication
  • Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials

Key Topics Covered:

1. Overview of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms

4. Mechanism of Microbiome Activity

4.1 Nature of Immune Response

4.1.1 Immunosuppressive Activity

4.1.2 Immunostimulatory Activity

4.2 Messengers Involves in Microbiome Mechanism

4.2.1 MAMPs/PAMPs

4.2.2 Microbial Metabolites As Messengers

4.2.3 Host Cytokines As Messengers

4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota

5.1 Technologies Used

5.1.1 iChip

5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)

5.1.3 Gut-on-a-Chip System

5.1.4 Colonic Stem Cell Construction

5.2 Harnessing & Engineering the Microbiome

5.2.1 Additive Approaches

5.2.2 Subtractive Approaches

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology

7.1 Microbiome Therapy

7.2 Precision Medicine

7.3 Drug discovery

7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases

8.1 Infection with Clostridium Difficile

8.2 Infection with Helicobacter Pylori

8.3 Bacterial Vaginosis

8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases

9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)

9.2 Alcoholic Liver Diseases (ALD)

9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders

10.1 Obesity

10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases

11.1 Microbiota & Allergic Diseases

11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology

12.1 Role of Microbiome in Immuno Oncology

12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression

13. Microbiome Application by Cancer Types

13.1 Gastric Cancer

13.2 Colorectal Cancer

13.3 Esophageal Cancer

13.4 Hepatocellular Carcinoma

13.5 Melanoma

13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology

14.1 Bacterial Approaches

14.1.1 Fecal Microbiota Transplantation (FMT)

14.1.2 Synthetic Bacteria

14.1.3 Microbial Culture

14.2 Microbiome as Vaccine

14.3 Microbiome as Small Molecules

14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis

15.1 Overview

15.2 Human Microbiome Market Segmentation

15.2.1 Regional Segmentation

15.2.2 Disease Based Segmentation

15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy

16.1 Microbiome Modulators in Clinical Trial

16.2 Cancer Related Clinical Trials

16.2.1 Preclinical & Discovery Phase

16.2.2 Active Clinical Trials

16.3 Clinical Trial Related To FMT

16.3.1 Clinical Trial for Recurrent C. difficile

16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)

16.3.3 Other FMT Related Clinical Trials

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase

17.1 Research

17.2 Preclinical

17.3 Clinical

17.4 Phase-I

17.5 Phase-I/II

17.6 Phase-II

17.7 Phase-II/III

17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight

18.1 Sodium Oligomannurarate – Shanghai Green Valley Pharmaceutical

18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology – Investments, Acquisitions & Collaborations by Leading Microbiome Companies

21. Blockades in the Microbiome Immunology Market

21.1 Stable Engraftment

21.2 Development of Clinically Relevant Sensors

21.3 Robustness and Evolutionary Stability of Genetic Circuits

21.4 Regulation, Safety and Biocontainment

22. Global Microbiome Immunology Market Future Panorama

23. Competitive Landscape

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/sk8m3s

Source

About the Author: Biotech Today

You might like